Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. exitaplasia

ExitAplasia

Reg-X310: new disruptive medicine for faster exit from aplasia afetr agressive chemotherapy of hematologic malignancies

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 ExitAplasia project word cloud

Explore the words cloud of the ExitAplasia project. It provides you a very rough idea of what is the project "ExitAplasia" about.

marking    shortening    faster    disrupt    extremely    with    stay    actual    hospital    health    triggers    70    tremendous    stakeholder    cells    global    reg    awarded    room    severe    x310    chemotherapy    breakthrough    turnover    2027    regeneration    toxicological    death    intravenous    changing    fragile    sterile    innovation    portion    opportunity    healthcare    red    recovery    exit    famous    broaden    costing    risk    25    white    french    explore    medicine    situation    paris    regstem    complete    speed    99    pasteur    7    business    points    aplasia    solution    patient    networks    acute    aggressive    dying    morbidity    patients    least    destruction    cancer    validation    infection    length    world    innovative    speeds    immunity    21    deficient    ce    pain    commercialisation    found    founded    10    difficult    accelerating    acquired    company    market    jobs    off    causes    clinical    exitaplasia    injection    improvement    days    relation    blood    feasibility    substantially    spin    leukaemia    14    2023    reformulate    start    treatment    game    share    decrease    deaths    million    day   

Project "ExitAplasia" data sheet

The following table provides information about the project.

Coordinator		 REGSTEM 

Organization address
address: 24 RUE DU FAUBOURG SAINT-JACQUES
city: PARIS
postcode: 75014
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country France [FR]
 Project website https://www.regstem.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-11-01   to  2019-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    REGSTEM FR (PARIS) coordinator 50˙000.00

Map

 Project objective

With more than 3.7 million new cases and 1.9 million deaths each year, cancer represents the second most important cause of death and morbidity in Europe; a significant portion is treated by chemotherapy, which triggers the destruction of red and white blood cells: aplasia. This aggressive treatment results in a severe deficient immunity and an extremely fragile health, which causes patients with leukaemia, for example, to stay 21 days at the hospital in a sterile room costing in average €25,000 per day. In this extremely difficult situation, RegStem has found the high-potential solution: the new Reg-X310 medicine which allows faster red and white blood cells regeneration, accelerating exit from aplasia and shortening hospital length of stay of at least 4 days. It is a tremendous improvement in relation to only existing medicine that speeds out aplasia for only one day. This breakthrough innovation will speed up recovery, decrease the risk of dying from a hospital-acquired infection (~7% less), and decrease healthcare cost for around €100,000/patient. Reg-X310 is a game-changing innovation which will substantially improve the treatment of aplasia and disrupt the market. Reg-X310 is being developed by RegStem, a French awarded innovative company, founded as a spin-off of the world-famous Pasteur Institute in Paris. The ExitAplasia project will allow the company to reformulate the Reg-X310 into an intravenous injection and to start the toxicological and clinical validation as well as the CE marking, necessary for the commercialisation in Europe. To accomplish this goal, RegStem will complete a feasibility study to further analyse users’ pain points and actual trends, as well as broaden European key stakeholder networks and explore new business opportunity. RegStem will lead the European and global acute leukaemia market with 10% market share in 2023 and up to 70% before 2027, which will result in €14 and €99 million turnover, and more than 20 new European jobs

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EXITAPLASIA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "EXITAPLASIA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

VINOQUANT11SUPERPLUS (2019)

A digital based system for measuring, showing and regulation of the complexe system of wine feremtation with high precision via a Bluetooth -Refractometer, a Software and a Bluetooth Thermostat

Read More  

DeltaQon (2019)

IOT and cloud computing for online medical analysis service platform

Read More  

MACCO (2019)

Bring social robots into reality with the first real world leading bartender (MACCO)

Read More